Loading candles…
Natco Pharma Limited, incorporated in 1981 and headquartered in Hyderabad, India, is a vertically integrated pharmaceutical company focused on research and development. The company develops, manufactures, and markets complex pharmaceutical products primarily in niche therapeutic areas such as oncology, including branded targeted therapies. Natco operates across multiple business segments including finished dosage formulations, active pharmaceutical ingredients, contract manufacturing, and a Crop Health Sciences division that provides pest management solutions leveraging its expertise in organic chemistry. It serves markets in India, the United States, and over 50 countries globally. The company emphasizes pharmaceutical exports of limited-competition molecules targeting high-entry-barrier markets while also operating in the agrochemical sector through its Crop Health Sciences division.
| Type | Details | Date |
|---|---|---|
| Audited Results - FY26 | To consider and approve the Audited financial results for the period ended March 31, 2026 | 29 May 2026 |
| Other | To consider Scheme of arrangement (demerger) | 24 Mar 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 and Interim dividend, if any for FY 2025-26 | 12 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 and 2nd Interim dividend for the Financial Year ending 2025-26 | 14 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 and interim dividend for the FY 25-26 | 12 Aug 2025 |
| Audited Results - FY25 | To consider and approve the Audited financial results for the period ended March 31, 2025 | 28 May 2025 |
Besseggen InfoTech LLP is a SEBI-registered stock broker (Reg. No. INZ000213450), member of NSE (90155 (Cash & F&O)) and BSE (6722 (Cash & F&O)). Investment in securities market are subject to market risks; read all related documents carefully before investing.